Table Graph
      published meta-analysis   sensitivity analysis   studies

placebo in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCOPE – Coalition V, 2022 (REV) 0.64 [0.16; 2.56] COVID-PEP Severity (Skipper), 2020 (REV) 0.99 [0.06; 15.88] 0.70[0.20; 2.42]COPE – Coalition V, 2022 (REV), COVID-PEP Severity (Skipper), 2020 (REV)20%1,860moderatenot evaluable clinical improvementdetailed resultsCOVID-PEP Severity (Skipper), 2020 (REV) 0.74 [0.47; 1.15] 0.74[0.47; 1.15]COVID-PEP Severity (Skipper), 2020 (REV)10%395NAnot evaluable clinical improvement (14-day)detailed resultsCOVID-PEP Severity (Skipper), 2020 (REV) 0.74 [0.47; 1.15] 0.74[0.47; 1.15]COVID-PEP Severity (Skipper), 2020 (REV)10%395NAnot evaluable hospitalizationdetailed resultsCOPE – Coalition V, 2022 (REV) 1.30 [0.88; 1.91] 1.30[0.88; 1.91]COPE – Coalition V, 2022 (REV)10%1,372NAnot evaluable mechanical ventilationdetailed resultsCOPE – Coalition V, 2022 (REV) 0.76 [0.26; 2.17] 0.76[0.26; 2.17]COPE – Coalition V, 2022 (REV)10%1,369NAnot evaluable ICU admissiondetailed resultsCOPE – Coalition V, 2022 (REV) 1.19 [0.62; 2.30] 1.19[0.62; 2.30]COPE – Coalition V, 2022 (REV)10%1,369NAnot evaluable adverse eventsdetailed resultsCOVID-PEP Severity (Skipper), 2020 (REV) 1.00 [0.02; 50.88] 1.00[0.02; 50.88]COVID-PEP Severity (Skipper), 2020 (REV)10%423NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-05-13 09:53 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 650 - roots T: 650

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons